|
KMID : 1141520230380010043
|
|
Endocrinology and Metabolism
2023 Volume.38 No. 1 p.43 ~ p.55
|
|
|
Renal Protection of Mineralocorticoid Receptor Antagonist, Finerenone, in Diabetic Kidney Disease
|
|
Kim Dong-Lim
Lee Seung-Eun
Kim Nan-Hee
|
|
|
Abstract
|
|
|
|
Chronic kidney disease (CKD) is the most common cause of end-stage renal disease in patients with type 2 diabetes mellitus (T2DM). CKD increases the risk of cardiovascular diseases; therefore, its prevention and treatment are important. The prevention ofdiabetic kidney disease (DKD) can be achieved through intensive glycemic control and blood pressure management. Additionally, DKD treatment aims to reduce albuminuria and improve kidney function. In patients with T2DM, renin-angiotensin-aldosteronesystem inhibitors, sodium glucose cotransporter 2 inhibitors, and glucagon-like peptide-1 receptor agonists can delay the progression of DKD. Hence, there is a need for novel treatments that can effectively suppress DKD progression. Finerenone is a first-in-classnonsteroidal mineralocorticoid receptor antagonist with clinically proven efficacy in improving albuminuria, estimated glomerular filtration rate, and risk of cardiovascular events in early and advanced DKD. Therefore, finerenone is a promising treatment option todelay DKD progression. This article reviews the mechanism of renal effects and major clinical outcomes of finerenone in DKD.
|
|
|
KEYWORD
|
|
|
Renal insufficiency, chronic, Diabetic nephropathies, Finerenone, Mineralocorticoid receptor antagonists, Diabetes mellitus
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
    
|
|